CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Advanced Life Sciences Holdings, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Advanced Life Sciences Holdings, Inc.
1440 Davey Road
Phone: (630) 739-6744p:630 739-6744 Woodridge, IL  60517-5316  United States Fax: (630) 739-6754f:630 739-6754

This company is no longer actively traded on any major stock exchange.

Business Summary
Advanced Life Sciences Holdings, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company’s lead candidate, Restanza, is a once-a-day oral antibiotic in development for the treatment of life-threatening infections including community-acquired bacterial pneumonia and biodefense pathogens including anthrax, plague and tularemia. ALS-886 is a therapeutic molecule in preclinical studies is being developed for the treatment intended to reduce and prevent the tissue damage associated with diseases such as Adult Respiratory Distress Syndrome (ARDS). ALS-357 is a natural product in preclinical studies has demonstrated specific anti-tumor activity against malignant melanoma. Preclinical studies have shown that direct injection of ALS-357 into grafted human tumors induced apoptosis, or programmed cell death, within the tumors.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/201012/31/2010YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board, Chief Executive Officer Michael T.Flavin 55 1/1/1999 1/1/1999
President, Chief Financial Officer, Director John L.Flavin 42 1/1/2010 6/1/2002
Executive Vice President, Chief Scientific Officer Ze-QiXu 49 10/1/2002 10/1/2002
7 additional Officers and Directors records available in full report.

Business Names
Business Name
ADLS
Advanced Life Sciences Holdings Inc.
Advanced Life Sciences Holdings, Inc.
Advanced Life Sciences, Inc.

General Information
Number of Employees: 16 (As of 12/31/2010)
Outstanding Shares: 10,787,538 (As of 4/8/2011)
Shareholders: 25
Stock Exchange: OTC
Federal Tax Id: 300296543
Fax Number: (630) 739-6754


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023